Array Biopharma has named Victor Sandor as its new chief medical officer, handing him responsibility for leading clinical, medical and regulatory strategy and operations across its Array portfolio.
This includes the Colorado, US-based company’s binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
Sandor said: “I am pleased to join the Array team at such an exciting time in the company’s evolution. In addition to the impressive portfolio of clinical stage assets in development by Array’s partners, I look forward to focusing on the development of binimetinib and filanesib, which each target patient populations with significant unmet medical need.”
He brings more than a decade of experience in the pharma and biotech industries to the role, and most recently served as senior VP for global clinical development at Incyte Corporation.
Prior to this he has held VP and CMO for oncology positions at Biogen Idec and also worked on oncology product development at AstraZeneca where he played a role in the registration of Arimidex for adjuvant use.
Ron Squarer, CEO at Array Biopharma, said: “Dr Sandor’s leadership, experience and vision will strengthen our clinical development efforts as we advance our late stage, wholly-owned assets towards commercialisation.
“With the possible near-term return of binimetinib to Array, his expertise will have significant unmet medical need.”